Thromboprophylaxis with original enoxaparin in oncology patients
Summary. Thrombosis is a common complication in oncology patients and is associated with a high mortality rate. Given the severe consequences of thromboembolic complications in cancer patients, the prevention of thrombosis is critical importance in clinical practice. Modern approaches to managing such patients include anticoagulant therapy, which helps reduce the risk of thrombus formation and improve prognosis. The latest guidelines from the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the National Comprehensive Cancer Network (NCCN) provide up-to-date recommendations on thromboprophylaxis and venous thromboembolism (VTE) management in cancer patients. One of the most effective and safest classes of anticoagulants for oncology patients is low-molecular-weight heparins (LMWHs), which have demonstrated high efficacy in preventing and treating thrombotic complications. Among the most frequently used anticoagulants is original enoxaparin (Clexane, pharmaceutical company Sanofi), which is considered the gold standard for managing oncology patients during hospitalization and chemotherapy, particularly for those with acute illnesses, infectious diseases (e.g. COVID-19 or bacterial sepsis), and acute thrombotic events in arterial or venous circulation. In these settings, original enoxaparin has established itself as a high-level therapeutic agent with proven efficacy and safety, as demonstrated in multiple studies conducted over the past 25 years. Its advantages include high efficacy in thrombosis prevention and reducing the risk of recurrence, predictable pharmacokinetics that eliminate the need for routine laboratory monitoring, convenient subcutaneous administration independent of gastrointestinal function, fewer drug interactions (which is especially relevant for patients undergoing chemotherapy), and superiority over oral anticoagulants in patients at risk of bleeding or with gastrointestinal complications. Thus, VTE remains a significant cause of morbidity and mortality in cancer patients, making timely thromboprophylaxis a crucial component in improving cancer patient survival.
Leave a comment